Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms
Philadelphia-negative classical myeloproliferative neoplasms (MPNs) include polycythemia
vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The 2016 …
vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The 2016 …
Primary myelofibrosis: 2017 update on diagnosis, risk‐stratification, and management
A Tefferi - American journal of hematology, 2016 - Wiley Online Library
Disease overview: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN)
characterized by stem cell‐derived clonal myeloproliferation that is often but not always …
characterized by stem cell‐derived clonal myeloproliferation that is often but not always …
MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis
P Guglielmelli, TL Lasho, G Rotunno… - Journal of Clinical …, 2018 - ascopubs.org
Purpose To develop a prognostic system for transplantation-age patients with primary
myelofibrosis (PMF) that integrates clinical, cytogenetic, and mutation data. Patients and …
myelofibrosis (PMF) that integrates clinical, cytogenetic, and mutation data. Patients and …
Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology
AT Gerds, J Gotlib, H Ali, P Bose, A Dunbar… - Journal of the National …, 2022 - jnccn.org
The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Abstract Janus kinase 2 (JAK2) mutations define polycythemia vera (PV). Calreticulin
(CALR) and myeloproliferative leukemia virus oncogene (MPL) mutations are specific to …
(CALR) and myeloproliferative leukemia virus oncogene (MPL) mutations are specific to …
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative
neoplasms with variable risk of evolution into post-PV and post-ET myelofibrosis, from now …
neoplasms with variable risk of evolution into post-PV and post-ET myelofibrosis, from now …
Targeted deep sequencing in polycythemia vera and essential thrombocythemia
Polycythemia vera (PV) is characterized by JAK2 and essential thrombocythemia (ET) by
JAK2, calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; …
JAK2, calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; …
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
E Rumi, D Pietra, C Pascutto… - Blood, The Journal …, 2014 - ashpublications.org
We studied the impact of driver mutations of JAK2, CALR,(calreticulin gene) or MPL on
clinical course, leukemic transformation, and survival of patients with primary myelofibrosis …
clinical course, leukemic transformation, and survival of patients with primary myelofibrosis …
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk‐stratification, and management
Abstract Disease overview Polycythemia Vera (PV) and essential thrombocythemia (ET) are
myeloproliferative neoplasms respectively characterized by erythrocytosis and …
myeloproliferative neoplasms respectively characterized by erythrocytosis and …
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms
A quarter of patients with essential thrombocythemia or primary myelofibrosis carry a driver
mutation of CALR, the calreticulin gene. A 52-bp deletion (type 1) and a 5-bp insertion (type …
mutation of CALR, the calreticulin gene. A 52-bp deletion (type 1) and a 5-bp insertion (type …